News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AstraZeneca PLC (AZN), BTG plc (BGC.L) Scrap Sepsis Drug as Trial Fails


8/8/2012 7:27:52 AM

An experimental drug for severe sepsis from AstraZeneca and BTG failed to help patients in a crucial mid-stage clinical trial and its development will now be halted, BTG said on Wednesday. Sepsis occurs when the body's immune system sets off a chain reaction and over-reacts to an infection, damaging vital organs. The news is a blow for both companies' drug pipelines, although the development of CytoFab, or AZD9773, was always viewed by analysts as risky. There are big potential rewards for a successful medicine to treat sepsis, which affects around 3 million people a year worldwide and has a 30 percent mortality rate. The drug industry, however, is littered with past failures in the area.

Read at Reuters
Read at Guardian
Read at Fox News
Read at InPharm.com
Read at Wall Street Journal


comments powered by Disqus
   
Sepsis

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES